{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:56:39Z","timestamp":1791536199850,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40265-021-01631-w","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T08:02:58Z","timestamp":1637136178000},"page":"2091-2101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A"],"prefix":"10.1007","volume":"81","author":[{"given":"Nowell","family":"Solish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Carruthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joely","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman G.","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor J.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"issue":"5","key":"1631_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/toxins10050208","volume":"10","author":"E Fonfria","year":"2018","unstructured":"Fonfria E, Maignel J, Lezmi S, Martin V, Splevins A, Shubber S, et al. The expanding therapeutic utility of botulinum neurotoxins. Toxins (Basel). 2018;10(5):208. https:\/\/doi.org\/10.3390\/toxins10050208.","journal-title":"Toxins (Basel)."},{"issue":"19","key":"1631_CR2","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818\u201326. https:\/\/doi.org\/10.1212\/WNL.0000000000002560.","journal-title":"Neurology"},{"issue":"3","key":"1631_CR3","doi-asserted-by":"publisher","first-page":"518e","DOI":"10.1097\/01.prs.0000475758.63709.23","volume":"137","author":"H Sundaram","year":"2016","unstructured":"Sundaram H, Signorini M, Liew S, Trindade de Almeida AR, Wu Y, Vieira Braz A, et al. Global aesthetics consensus: botulinum toxin type A\u2013evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plast Reconstr Surg. 2016;137(3):518e-e529. https:\/\/doi.org\/10.1097\/01.prs.0000475758.63709.23.","journal-title":"Plast Reconstr Surg"},{"key":"1631_CR4","unstructured":"Allergan. BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use prescribing information. 2020. https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/20190620-BOTOX-100-and-200-Units-v3-0USPI1145-v2-0MG1145.pdf. Accessed 4 Aug 2021."},{"key":"1631_CR5","unstructured":"Ipsen. DYSPORT (abobotulinumtoxinA) for injection, for intramuscular use prescribing information. 2018. https:\/\/www.ipsen.com\/websites\/Ipsen_Online\/wp-content\/uploads\/sites\/9\/2019\/01\/21084019\/Dysport_Full_Prescribing_Information.pdf. Accessed 1 Mar 2021."},{"key":"1631_CR6","unstructured":"Allergan. BOTOX Cosmetic (onabotulinumtoxinA) for injection, for intramuscular use prescribing information. 2019. https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/20190626-BOTOX-Cosmetic-Insert-72715US10-Med-Guide-v2-0MG1145.pdf. Accessed 12 Mar 2021."},{"key":"1631_CR7","unstructured":"Merz. XEOMIN (incobotulinumtoxinA) for injection, for intramuscular or intraglandular use prescribing information. 2019. https:\/\/www.xeominaesthetic.com\/wp-content\/uploads\/2019\/05\/XEOMIN-Full-Prescribing-Information-including-MedGuide.pdf. Accessed 12 Mar 2021."},{"issue":"3","key":"1631_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3111\/13696998.2011.653726","volume":"15","author":"KD Sethi","year":"2012","unstructured":"Sethi KD, Rodriguez R, Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ. 2012;15(3):419\u201323. https:\/\/doi.org\/10.3111\/13696998.2011.653726.","journal-title":"J Med Econ"},{"issue":"3","key":"1631_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00415-020-10217-7","volume":"286","author":"C Comella","year":"2020","unstructured":"Comella C, Ferreira JJ, Pain E, Azoulai M, Om S. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. J Neurol. 2020;286(3):903\u201312. https:\/\/doi.org\/10.1007\/s00415-020-10217-7.","journal-title":"J Neurol"},{"key":"1631_CR10","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.2147\/PPA.S106560","volume":"10","author":"M Poliziani","year":"2016","unstructured":"Poliziani M, Koch M, Liu X. Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia. Patient Prefer Adherence. 2016;10:1601\u20138. https:\/\/doi.org\/10.2147\/PPA.S106560.","journal-title":"Patient Prefer Adherence"},{"key":"1631_CR11","unstructured":"Revance. Data on file."},{"issue":"3","key":"1631_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mdc3.12613","volume":"5","author":"J Jankovic","year":"2018","unstructured":"Jankovic J, Truong D, Patel AT, Brashear A, Evatt M, Rubio RG, et al. Injectable daxibotulinumtoxinA in cervical dystonia: a phase 2 dose-escalation multicenter study. Mov Disord Clin Pract. 2018;5(3):273\u201382. https:\/\/doi.org\/10.1002\/mdc3.12613.","journal-title":"Mov Disord Clin Pract."},{"key":"1631_CR13","doi-asserted-by":"crossref","unstructured":"Jankovic J, Comella C, Hauser RA, Patel AT, Gross TM, Rubio RG, et al. ASPEN-1. A phase 3 trial evaluating the efficacy, duration of effect, and safety of DaxibotulinumtoxinA for Injection in the treatment of cervical dystonia. Poster presented at: TOXINS 2021; January 16\u201317, 2021; Virtual.","DOI":"10.1016\/j.toxicon.2020.11.410"},{"key":"1631_CR14","unstructured":"Overman D. DaxibotulinumtoxinA Injection for upper-limb spasticity study receives positive results [press release]. February 24, 2021. https:\/\/rehabpub.com\/conditions\/neurological\/stroke-neurological\/daxibotulinumtoxina-injection-for-upper-limb-spasticity-study-receives-positive-results\/. Accessed 4 Aug 2021."},{"issue":"1","key":"1631_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/PRS.0000000000006327","volume":"145","author":"JD Carruthers","year":"2020","unstructured":"Carruthers JD, Fagien S, Joseph JH, Humphrey SD, Biesman BS, Gallagher CJ, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45\u201358. https:\/\/doi.org\/10.1097\/PRS.0000000000006327.","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"1631_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/dss.0000000000002531","volume":"47","author":"SG Fabi","year":"2021","unstructured":"Fabi SG, Cohen JL, Green LJ, Dhawan S, Kontis TC, Baumann L, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. Dermatol Surg. 2021;47(1):48\u201354. https:\/\/doi.org\/10.1097\/dss.0000000000002531.","journal-title":"Dermatol Surg"},{"key":"1631_CR17","unstructured":"Solish N, Green JB, Fagien S, Bertucci V, Gallagher CJ, Liu Y, et al. A phase 2a dose-escalation study to evaluate the efficacy and safety of DaxibotulinumtoxinA for Injection for the treatment of dynamic forehead lines following glabellar line injections: an interim analysis. Poster presented at: MauiDerm 2020; January 25\u201329, 2020; Maui, HI."},{"issue":"2","key":"1631_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.toxicon.2011.05.012","volume":"58","author":"HF Stone","year":"2011","unstructured":"Stone HF, Zhu Z, Thach TQ, Ruegg CL. Characterization of diffusion and duration of action of a new botulinum toxin type A formulation. Toxicon. 2011;58(2):159\u201367. https:\/\/doi.org\/10.1016\/j.toxicon.2011.05.012.","journal-title":"Toxicon"},{"issue":"2","key":"1631_CR19","first-page":"31","volume":"7","author":"TJ Walker","year":"2014","unstructured":"Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol. 2014;7(2):31\u20139.","journal-title":"J Clin Aesthet Dermatol."},{"key":"1631_CR20","doi-asserted-by":"crossref","unstructured":"Malmirchegini R, Too P, Oliyai C, Joshi A. Revance's novel peptide excipient, RTP004, and its role in stabilizing DaxibotulinumtoxinA (DAXI) against aggregation. Poster presented at: TOXINS 2019; January 16\u201319, 2019; Copenhagen, Denmark.","DOI":"10.1016\/j.toxicon.2018.11.174"},{"issue":"1","key":"1631_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/biohorizons\/hzp001","volume":"2","author":"V Sebbage","year":"2009","unstructured":"Sebbage V. Cell-penetrating peptides and their therapeutic applications. Biosci Horiz. 2009;2(1):64\u201372.","journal-title":"Biosci Horiz."},{"key":"1631_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3762\/bjnano.11.10","volume":"11","author":"I Ruseska","year":"2020","unstructured":"Ruseska I, Zimmer A. Internalization mechanisms of cell-penetrating peptides. Beilstein J Nanotechnol. 2020;11:101\u201323. https:\/\/doi.org\/10.3762\/bjnano.11.10.","journal-title":"Beilstein J Nanotechnol"},{"key":"1631_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105231","volume":"162","author":"N Vale","year":"2020","unstructured":"Vale N, Duarte D, Silva S, Correia AS, Costa B, Gouveia MJ, et al. Cell-penetrating peptides in oncologic pharmacotherapy: a review. Pharmacol Res. 2020;162: 105231. https:\/\/doi.org\/10.1016\/j.phrs.2020.105231.","journal-title":"Pharmacol Res"},{"issue":"3","key":"1631_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/14712598.2021.1823368","volume":"21","author":"K Kurrikoff","year":"2021","unstructured":"Kurrikoff K, Vunk B, Langel \u00dc. Status update in the use of cell-penetrating peptides for the delivery of macromolecular therapeutics. Expert Opin Biol Ther. 2021;21(3):361\u201370. https:\/\/doi.org\/10.1080\/14712598.2021.1823368.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"1631_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/psc.3300","volume":"27","author":"S Reissmann","year":"2021","unstructured":"Reissmann S, Filatova MP. New generation of cell-penetrating peptides: functionality and potential clinical application. J Pept Sci. 2021;27(5): e3300. https:\/\/doi.org\/10.1002\/psc.3300.","journal-title":"J Pept Sci"},{"issue":"6","key":"1631_CR26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2174\/1381612826666201019102640","volume":"27","author":"M Korivi","year":"2020","unstructured":"Korivi M, Huang YW, Liu BR. Cell-penetrating peptides as a potential drug delivery system for effective treatment of diabetes. Curr Pharm Des. 2020;27(6):816\u201325. https:\/\/doi.org\/10.2174\/1381612826666201019102640.","journal-title":"Curr Pharm Des"},{"key":"1631_CR27","doi-asserted-by":"crossref","unstructured":"Weisemann J, Rummel A, Oliyai C, Too P, Joshi A. novel peptide excipient RTP004 enhances the binding of botulinum neurotoxin A cell binding domain Hc to rat brain synaptosomes. Poster presented at: TOXINS 2019; January 16\u201319, 2019; Copenhagen, Denmark.","DOI":"10.1016\/j.toxicon.2018.11.273"},{"issue":"3","key":"1631_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000618","volume":"18","author":"L Yin","year":"2020","unstructured":"Yin L, Masuyer G, Zhang S, Zhang J, Miyashita SI, Burgin D, et al. Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy. PLoS Biol. 2020;18(3): e3000618. https:\/\/doi.org\/10.1371\/journal.pbio.3000618.","journal-title":"PLoS Biol"},{"key":"1631_CR29","unstructured":"Glogau RG, Waugh JM. Preclinical transcutaneous flux experiments using a macromolecule transport system (MTS) peptide for delivery of botulinum toxin type A. Poster presented at: Annual Meeting of the American Academy of Dermatology; February 1\u20138, 2008; San Antonio, TX."},{"key":"1631_CR30","doi-asserted-by":"crossref","unstructured":"Smyth T, Oliyai C, Joshi A. Stabilizing effect of RTP004 on non-specific surface adsorption in drug product manufacturing of daxibotulinumtoxinA (DAXI). Poster presented at: TOXINS 2019; January 16\u201319, 2019; Copenhagen, Denmark.","DOI":"10.1016\/j.toxicon.2018.11.253"},{"issue":"Suppl 1","key":"1631_CR31","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1097\/DSS.0000000000000276","volume":"41","author":"E Garcia-Murray","year":"2015","unstructured":"Garcia-Murray E, Velasco Villasenor ML, Acevedo B, Luna S, Lee J, Waugh JM, et al. Safety and efficacy of RT002, an injectable botulinum toxin type A, for treating glabellar lines: results of a phase 1\/2, open-label, sequential dose-escalation study. Dermatol Surg. 2015;41(Suppl 1):S47-55. https:\/\/doi.org\/10.1097\/DSS.0000000000000276.","journal-title":"Dermatol Surg"},{"issue":"11","key":"1631_CR32","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","volume":"43","author":"J Carruthers","year":"2017","unstructured":"Carruthers J, Solish N, Humphrey S, Rosen N, Muhn C, Bertucci V, et al. Injectable DaxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatol Surg. 2017;43(11):1321\u201331. https:\/\/doi.org\/10.1097\/DSS.0000000000001206.","journal-title":"Dermatol Surg"},{"issue":"4","key":"1631_CR33","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","volume":"82","author":"V Bertucci","year":"2020","unstructured":"Bertucci V, Solish N, Kaufman-Janette J, Yoelin S, Shamban A, Schlessinger J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838\u201345. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1313.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1631_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/dss.0000000000002463","volume":"47","author":"JB Green","year":"2021","unstructured":"Green JB, Mariwalla K, Coleman K, Ablon G, Weinkle SH, Gallagher CJ, et al. A large, open-label, phase 3 safety study of DaxibotulinumtoxinA for Injection in glabellar lines: a focus on safety from the SAKURA 3 study. Dermatol Surg. 2021;47(1):42\u20136. https:\/\/doi.org\/10.1097\/dss.0000000000002463.","journal-title":"Dermatol Surg"},{"key":"1631_CR35","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.1097\/DSS.0000000000001364","volume":"43","author":"V Bertucci","year":"2017","unstructured":"Bertucci V, Humphrey S, Carruthers J, Solish N, Muhn C, Swift A, et al. Comparing injectable daxibotulinumtoxinA and onabotulinumtoxinA in moderate and severe glabellar lines: additional analyses from a phase 2, randomized, dose-ranging, double-blind, multicenter study. Dermatol Surg. 2017;43:S262\u201373. https:\/\/doi.org\/10.1097\/DSS.0000000000001364.","journal-title":"Dermatol Surg"},{"key":"1631_CR36","unstructured":"Evolus. JEUVEAU (prabotulinumtoxinA-xvfs) for injection, for intramuscular use prescribing information. 2020. https:\/\/info.evolus.com\/hubfs\/Prescribing%20Info_20200130.pdf. Accessed 12 Mar 2021."},{"key":"1631_CR37","unstructured":"Dystonia Medical Research Foundation. Cervical dystonia. https:\/\/dystonia-foundation.org\/what-is-dystonia\/types-dystonia\/cervical-dystonia\/. Accessed 14 Mar 2021."},{"key":"1631_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fneur.2017.00035","volume":"8","author":"MF Contarino","year":"2017","unstructured":"Contarino MF, Van Den Dool J, Balash Y, Bhatia K, Giladi N, Koelman JH, et al. Clinical practice: evidence-based recommendations for the treatment of cervical dystonia with botulinum toxin. Front Neurol. 2017;8:35. https:\/\/doi.org\/10.3389\/fneur.2017.00035.","journal-title":"Front Neurol"},{"key":"1631_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2377-14-91","volume":"14","author":"WA Marsh","year":"2014","unstructured":"Marsh WA, Monroe DM, Brin MF, Gallagher CJ. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurol. 2014;14:91. https:\/\/doi.org\/10.1186\/1471-2377-14-91.","journal-title":"BMC Neurol"},{"key":"1631_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.7916\/D84X56BF","volume":"4","author":"VG Evidente","year":"2014","unstructured":"Evidente VG, Pappert EJ. Botulinum toxin therapy for cervical dystonia: the science of dosing. Tremor Other Hyperkinet Mov (N Y). 2014;4:273. https:\/\/doi.org\/10.7916\/D84X56BF.","journal-title":"Tremor Other Hyperkinet Mov (N Y)."},{"issue":"2","key":"1631_CR41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00702-014-1253-8","volume":"122","author":"D Dressler","year":"2015","unstructured":"Dressler D, Tacik P, Saberi FA. Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm (Vienna). 2015;122(2):297\u2013300. https:\/\/doi.org\/10.1007\/s00702-014-1253-8.","journal-title":"J Neural Transm (Vienna)"},{"key":"1631_CR42","first-page":"211","volume-title":"Therapy with botulinum toxin","author":"E Consky","year":"1994","unstructured":"Consky E, Lang A. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p. 211\u201337."},{"key":"1631_CR43","doi-asserted-by":"crossref","unstructured":"Brashear A, Truong D, Comella C, Jankovic J, Patel A, Prawdzik G, et al. DaxibotulinumtoxinA for Injection in adults with cervical dystonia from a phase 2 dose-escalation multicenter study. Poster presented at: American Academy of Neurology 2019, May 4-10, 2019; Philadelphia, PA.","DOI":"10.1212\/WNL.92.15_supplement.P4.8-012"},{"key":"1631_CR44","unstructured":"ClinicalTrials.gov. Single treatment of DaxibotulinumtoxinA for Injection in adults with isolated cervical dystonia (ASPEN-1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03608397?term=cervical+dystonia&cond=daxibotulinumtoxinA&draw=2&rank=1. Accessed 30 July 2020."},{"key":"1631_CR45","unstructured":"ClinicalTrials.gov. Long-term safety and efficacy of repeat treatments of DaxibotulinumtoxinA for Injection in adults with isolated cervical dystonia (ASPEN-OLS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03617367?term=DaxibotulinumtoxinA&cond=Cervical+Dystonia&phase=2&fund=2&draw=2&rank=1. Accessed 19 Nov 2020."},{"issue":"1\u20132","key":"1631_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","volume":"308","author":"CL Comella","year":"2011","unstructured":"Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S, US XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1\u20132):103\u20139. https:\/\/doi.org\/10.1016\/j.jns.2011.05.041.","journal-title":"J Neurol Sci"},{"issue":"9","key":"1631_CR47","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","volume":"65","author":"CL Comella","year":"2005","unstructured":"Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65(9):1423\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000183055.81056.5c.","journal-title":"Neurology"},{"issue":"1","key":"1631_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/pl00007848","volume":"249","author":"M Naumann","year":"2002","unstructured":"Naumann M, Yakovleff A, Durif F, BOTOX Cervical Dystonia Prospective Study Group. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol. 2002;249(1):57\u201363. https:\/\/doi.org\/10.1007\/pl00007848.","journal-title":"J Neurol"},{"issue":"2","key":"1631_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","volume":"10","author":"J Frevert","year":"2010","unstructured":"Frevert J. Content of botulinum neurotoxin in Botox\u00ae\/Vistabel\u00ae, Dysport\u00ae\/Azzalure\u00ae, and Xeomin\u00ae\/Bocouture\u00ae. Drugs R D. 2010;10(2):67\u201373. https:\/\/doi.org\/10.2165\/11584780-000000000-00000.","journal-title":"Drugs R D"},{"key":"1631_CR50","unstructured":"U. S. Food and Drug Administration. Center for Drug Evaluation and Research. Medical review: Dysport - abobotulinumtoxin A. 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/125274Orig1s001MedR.pdf. Accessed 25 Feb 2021."},{"issue":"1","key":"1631_CR51","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1006\/exnr.2000.7583","volume":"168","author":"H Bigalke","year":"2001","unstructured":"Bigalke H, Wohlfarth K, Irmer A, Dengler R. Botulinum A toxin: dysport improvement of biological availability. Exp Neurol. 2001;168(1):162\u201370. https:\/\/doi.org\/10.1006\/exnr.2000.7583.","journal-title":"Exp Neurol"},{"issue":"4","key":"1631_CR52","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00702-009-0200-6","volume":"116","author":"B Mohammadi","year":"2009","unstructured":"Mohammadi B, Kollewe K, Wegener M, Bigalke H, Dengler R. Experience with long-term treatment with albumin-supplemented botulinum toxin type A. J Neural Transm (Vienna). 2009;116(4):437\u201341. https:\/\/doi.org\/10.1007\/s00702-009-0200-6.","journal-title":"J Neural Transm (Vienna)"},{"issue":"12","key":"1631_CR53","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/toxins10120535","volume":"10","author":"M Field","year":"2018","unstructured":"Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, et al. AbobotulinumtoxinA (Dysport\u00ae), OnabotulinumtoxinA (Botox\u00ae), and IncobotulinumtoxinA (Xeomin\u00ae) neurotoxin content and potential implications for duration of response in patients. Toxins (Basel). 2018;10(12):535. https:\/\/doi.org\/10.3390\/toxins10120535.","journal-title":"Toxins (Basel)."},{"issue":"11","key":"1631_CR54","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1097\/dss.0000000000001903","volume":"45","author":"KR Beer","year":"2019","unstructured":"Beer KR, Shamban AT, Avelar RL, Gross JE, Jonker A. Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatol Surg. 2019;45(11):1381\u201393. https:\/\/doi.org\/10.1097\/dss.0000000000001903.","journal-title":"Dermatol Surg"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01631-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01631-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01631-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T10:40:35Z","timestamp":1726137635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01631-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":54,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1631"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01631-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"13 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Neither honoraria nor payments were made for authorship. The open access fee for the manuscript was funded by Revance Therapeutics, Inc. Writing and editorial assistance was provided to the authors by Evidence Scientific Solutions, Philadelphia, PA, and funded by Revance Therapeutics, Inc., Newark, CA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NS, JC, and JK are investigators for Revance Therapeutics, Inc. RGR, TMG, and CJG are employees and stockholders at Revance Therapeutics, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in the drafting, critical revision, and approval of the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}